Atara biotherapeutics announces plans to submit tab-cel® bla in q2 2024 following fda agreement on comparability

Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported important progress related to the regulatory pathway for tabelecleucel (tab-cel®) in the u.s. following productive discussions between atara and the u.s. food and drug administration (fda), the fda and atara.
ATRA Ratings Summary
ATRA Quant Ranking